

End point title: Number of Subjects With Sustained Reduction in Disability (SRD) Assessed by EDSS (After Alemtuzumab Treatment) at Year 2 of the Extension Study

Statistical analysis title	Switch CAMMS323/03409 (Post Alemtuzumab)
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	IFNB1a/Alemtuzumab Switch CAMMS323/03409 (Post Alemtuzumab)
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SRD
Point estimate	16.92
Confidence interval	
level	95%
sides	2-sided
lower limit	9.75
upper limit	28.47
Statistical analysis title	Switch CAMMS324/03409 (Post Alemtuzumab)
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	IFNB1a/Alemtuzumab Switch CAMMS324/03409 (Post Alemtuzumab)
Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SRD
Point estimate	13.89
Confidence interval	
level	95%
sides	2-sided
lower limit	8.47
upper limit	22.33